Laurie Matt-Amaral, MD
Medical Oncology · Akron, OHNPI 1306096409
Payments from drug & device makers
Across 63 payments — averaging $191.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$7K
- Pfizer$3K
- Foundation Medicine, Inc.$389
- Johnson & Johnson$363
- Seagen Inc.$297
- Lilly USA, LLC$218
- plus $2K from 16 others
What the payments were for
- Consulting fees$6,53254%
- Speaking & faculty fees$2,62522%
- Food & beverage$1,99417%
- Education$9218%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 1 | $6,532 |
| Pfizer | 2 | $2,702 |
| Foundation Medicine, Inc. | 3 | $389 |
| Johnson & Johnson | 7 | $363 |
| Seagen Inc. | 5 | $297 |
| Lilly USA, LLC | 3 | $218 |
| AbbVie | 4 | $170 |
| Incyte Corporation | 3 | $169 |
| Eisai Inc. | 8 | $167 |
| Merck | 3 | $165 |
| Intera Oncology, Inc | 1 | $150 |
| AstraZeneca | 3 | $143 |
| Amgen | 2 | $132 |
| GSK | 4 | $97 |
| Astellas Pharma US Inc | 1 | $90 |
| Caris MPI, Inc. | 4 | $70 |
| Genmab U.S., Inc. | 3 | $67 |
| Beigene USA, Inc. | 1 | $50 |
| Legend Biotech USA Inc. | 2 | $36 |
| Baxter Healthcare | 1 | $27 |
| Novartis | 1 | $24 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,072 in reported general payments places this provider in the 45th percentile of 157 medical oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 90 | $1,267,752 |
| FabhaltaIptacopan Hcl | 20 | $881,930 |
| RevlimidLenalidomide | 45 | $879,263 |
| CalquenceAcalabrutinib Maleate | 55 | $829,651 |
| XtandiEnzalutamide | 56 | $763,784 |
| Lenalidomide | 45 | $718,085 |
| IbrancePalbociclib | 46 | $703,285 |
| ErleadaApalutamide | 48 | $687,502 |
| PomalystPomalidomide | 22 | $542,396 |
| KisqaliRibociclib Succinate | 20 | $303,820 |
| InlytaAxitinib | 13 | $267,865 |
| BrukinsaZanubrutinib | 17 | $253,160 |
| JakafiRuxolitinib Phosphate | 14 | $244,031 |
| SprycelDasatinib | 13 | $224,428 |
| VerzenioAbemaciclib | 14 | $197,500 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisFabhalta, Kisqali, Promacta | $24 | $1,311,23158 claims |
| PfizerIbrance, Inlyta, Eliquis | $2,702 | $1,166,358282 claims |
| AstraZenecaCalquence | $143 | $829,65155 claims |
| Johnson & JohnsonErleada, Xarelto | $363 | $796,523157 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel | $6,532 | $766,82435 claims |
| Astellas Pharma US IncXtandi | $90 | $763,78456 claims |
| Beigene USA, Inc.Brukinsa | $50 | $253,16017 claims |
| Incyte CorporationJakafi | $169 | $244,03114 claims |
| Lilly USA, LLCVerzenio | $218 | $197,50014 claims |
| AbbVieCreon | $170 | $10,09911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 157 medical oncology providers in Ohio.
Other medical oncology in Akron
- Michael WangBelpre$21.6M
- Kai HeColumbus$10.9M
- Timothy BurnsColumbus$7.2M
- Dwight OwenColumbus$6.8M
- Jennifer SelfridgeCleveland$6.3M
- Moshe OrnsteinCleveland$6.1M
- David CarboneColumbus$5.4M
- Manisha ShahColumbus$4.3M
- Gregory OttersonColumbus$4.1M
- Marcelo BonomiColumbus$4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.